Around 15% of strokes are haemorrhagic (due to bleeding in or around the brain). This guide explains the two different types of stroke caused by a bleed, intracerebral and subarachnoid haemorrhage, and how they are diagnosed and treated.
In a study published in the journal, The Lancet Neurology, scientists analysed data from more than 1,600 adults with cavernoma - a cluster of abnormal blood vessels in the brain - to generate estimates of risk. The findings could help both doctors and patients to make informed decisions about their treatment.
Intracerebral haemorrhage (ICH) is a type of stroke, which is caused by bleeding in the brain, ultimately leading to brain damage, disability and often death. We currently know very little about the biological changes that occur in the brain after intracerebral haemorrhage.
The CROMIS-2 study investigated whether signs of small brain bleeds on routine brain scans can help us understand which ischaemic stroke patients with atrial fibrillation are at increased risk of a bleed in the brain when on anticoagulant ‘blood thinning’ drugs.
Postgraduate fellowship: What is the impact of damaged thinking ability caused by a spontaneous bleed in the brain?
This study will investigate whether reducing blood pressure can stop bleeding in the brain after thrombolysis (a clot-busting treatment for stroke) and improve patient's outcomes.
Led by the University of Nottingham, a new international study investigated whether patients with a spontaneous bleed in the brain (intracerebral haemorrhage) could benefit from this drug, if delivered as an emergency treatment. An intracerebral haemorrhage is a type of stroke.
This research will investigate 2000 drugs that are already known to be safe for use in humans to see if they could help reduce the amount of damage to the brain an intracerebral haemorrhage (a type of stroke caused by a bleed in the brain) causes.
Published online first in the journal Neurology, a new study suggests that people with AF who have an ICH due to their medication have similar outcomes whether they're on a NOAC or a vitamin K antagonist drug.
PRESTIGE-AF is a new multi-million Euro initiative funded by the European Commission has been set up to help prevent stroke in patients with existing conditions.